A multi-centred retrospective cohort study comparing JAK inhibitor therapies in moderate-to-severe ulcerative colitis
Clicks: 1
ID: 315010
2026
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This
article has not been analysed, so there is no overall score —
reader engagement is measured and shown alongside.
Reader Engagement
0.0
/100
1 views
0 readers
AI Quality Assessment
Not analyzed
Readership in this journal
Ranked #15 of 38 articles by views in Crohn s & Colitis 360
Most read
Least read
Bar heights use a square-root scale.
Mint this article as an NFT
Not yet mintedCreate a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.
5
SUSD
one-off · no wallet required
Abstract
Abstract Background Tofacitinib, filgotinib and upadacitinib are JAK inhibitors (JAKi) that have demonstrated efficacy in ulcerative colitis (UC) against placebo. This study aims to compare the clinical efficacy between these drugs. Methods This is a multi-centred, retrospective cohort study. Patients with UC starting a JAKi were recruited between 2018 and 2024 when starting their first JAKi. Clinical remission and response, based on clinical scores, calprotectin and endoscopic measurement were assessed at 3- and 6-months. Both independent and combined variable outcomes were analysed. Results 270 patients were included in the analysis, of which 70 (26%) were on upadacitinib, 51 (19%) on filgotinib and 149 (55%) on tofacitinib. Clinical, biochemical and endoscopic remission at 6-months was 91%, 71% and 80% for upadacitinib; 78%, 67% and 50% for filgotinib; 73%, 51% and 44% for tofacitinib. Upadacitinib demonstrated significantly greater clinical response (p = 0.027) and remission (p = 0.037) rates at 6-months than tofacitinib. Drug persistence at 12-months was 86% for upadacitinib, 72% for filgotinib and 69% for tofacitinib. Upadacitinib demonstrated significantly greater 6-month remission rates compared to tofacitinib in the bio-exposed cohort (71% v 52%, p = 0.022) and in the bio-naïve cohort (93% v 50%, p = 0.009). The incidence rates for hospital admissions were 10.2, 21.9, and 14.1 and for colectomies were 6.7, 10.0 and 5.0 per 1000 patient months at risk for upadacitinib, filgotinib and tofacitinib, respectively. Conclusion This study demonstrates that upadacitinib is more likely to achieve 6-month response and remission compared to tofacitinib. In both bio-naïve and bio-exposed patients, upadacitinib was more likely to achieve remission at 6-months. The efficacy of JAKi does not appear diminished by prior biologic use.
| Reference Key |
openalex_W7162428600
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | Aditi Kumar, Joshua Baxter, Peter Rimmer, Ben Noble, Joshua Bower, Mujeeb Ullah Makki, Ayiesha Hatta, A Chikhlia, Jonathan Cheesbrough, Ben Disney, Josh Muir, Mariya Karova, Jeffrey Butterworth, Nidhi Sagar, Ismaeel Al-Talib, J Nahal, Nasima Ali, Vandana Sagar, Fumi Varyani, Sam Smith, Stephanie Bourne, Yu-Kai Hsu, Almoiez Eltahir, Shanika de Silva, P Harvey |
| Journal | Crohn s & Colitis 360 |
| Year | 2026 |
| DOI |
10.1093/crocol/otag045
|
| URL | |
| Keywords | Keywords not found |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.